专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2010116412A Method and composition for treating schizophrenia 审中-公开
标题翻译：方法和组合物治疗苦参碱
公开(公告)号：JP2010116412A
公开(公告)日：2010-05-27
申请号：JP2010013671
申请日：2010-01-25
申请人： Medivation Neurology Inc , メディベイションニューロロジー, インコーポレイテッド
发明人： BACHURIN SERGEI O , GRIGORIEV VLADIMIR V , MOROZOVA MARGARITA A , BENIASHVILI ALLAN G
IPC分类号： A61K31/437 , A61K45/00 , A61P25/18 , C07D471/04
CPC分类号： A61K31/437 , A61K31/444
摘要： PROBLEM TO BE SOLVED: To provide treatment of schizophrenia, an additional or alternative therapeutic method for preventing and/or delaying onset and/or symptom expression of schizophrenia. SOLUTION: The treatment of schizophrenia and/or methods, compounds and compositions for preventing and/or delaying onset and/or symptom expression of schizophrenia by using hydrogenated [4,3-b]indoles or pharmaceutically acceptable salts thereof are provided. The methods and the compositions may include a compound including the compound dimebon (2,8-dimethyl-5-(2-(6-methyl-3-pyridyl)ethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole dibasic acid salt) without limitation. COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：待解决的问题：提供精神分裂症的治疗，用于预防和/或延迟精神分裂症的发作和/或症状表现的另外或替代的治疗方法。提供了通过使用氢化[4,3-b]吲哚或其药学上可接受的盐来治疗精神分裂症和/或用于预防和/或延迟精神分裂症发作和/或症状表现的方法，化合物和组合物。方法和组合物可以包括化合物，包括化合物二甲基（2,8-二甲基-5-（2-（6-甲基-3-吡啶基）乙基）-2,3,4,5-四氢-1H-吡啶并[ [4,3-b]吲哚二元酸盐）。版权所有（C）2010，JPO＆INPIT

2. 发明申请

WO2009111540A1 METHODS FOR PREPARING PYRIDYLETHYL-SUBSTITUTED CARBOLINES 审中-公开
标题翻译：制备吡啶基取代的碳的方法
公开(公告)号：WO2009111540A1
公开(公告)日：2009-09-11
申请号：PCT/US2009/035992
申请日：2009-03-04
申请人： MEDIVATION NEUROLOGY, INC. , WOLLOWITZ, Susan , KATAISTO, Erik, W.
发明人： WOLLOWITZ, Susan , KATAISTO, Erik, W.
IPC分类号： A01N43/42
CPC分类号： C07D471/04
摘要： Methods of preparing pyridylethyl-substituted carbolines under reaction conditions that use fewer molar equivalents of MVP to produce the pyridylethyl-substituted carboline as compared to reported methods of preparing pyridylethyl-substituted carbolines using MVP are provided. Also provided are methods of preparing a pyridylethyl-substituted carboline using non-commercial MVP.
摘要翻译：提供了与使用MVP制备吡啶基乙基取代的咔啉的报道方法相比，在使用较少摩尔当量的MVP产生吡啶基乙基取代的咔啉的反应条件下制备吡啶基乙基取代的咔啉的方法。还提供了使用非商业MVP制备吡啶基乙基取代的咔啉的方法。

3. 发明申请

WO2009039420A1 METHODS AND COMPOSITIONS FOR TREATING NEURONAL DEATH MEDIATED OCULAR DISEASES 审中-公开
标题翻译：治疗神经元死亡介导的眼部疾病的方法和组合物
公开(公告)号：WO2009039420A1
公开(公告)日：2009-03-26
申请号：PCT/US2008077090
申请日：2008-09-19
申请人： MEDIVATION NEUROLOGY INC , HUNG DAVID T
发明人： HUNG DAVID T
IPC分类号： A01N43/38 , A61K31/405
CPC分类号： A61K31/405
摘要： The invention provides methods for treating and/or preventing and/or slowing the onset and/or development of a neuronal death mediated ocular disease using hydrogenated pyrido[4,3- b]indoles, such as dimebon.
摘要翻译：本发明提供了使用氢化吡啶并[4,3-b]吲哚（例如Dimebon）治疗和/或预防和/或减缓神经元死亡介导的眼部疾病的发生和/或发展的方法。

4. 发明申请

WO2008073231A1 MEANS FOR THE TREATMENT OF ACUTE AND CHRONIC DISORDERS OF CEREBRAL CIRCULATION, INCLUDING INSULT, BASED ON HYDROGENATED PYRIDO (4, 3-B) INDOLES (VARIANTS), PHARMACOLOGICAL MEANS BASED THEREON AND METHOD FOR THE USE THEREOF 审中-公开
标题翻译：用于治疗基于氢化吡啶（4,3-B）吲哚（变体），基于其的药理学方法及其使用方法的脑血管循环的急性和慢性疾病的包括失败的手段
公开(公告)号：WO2008073231A1
公开(公告)日：2008-06-19
申请号：PCT/US2007/024626
申请日：2007-11-30
申请人： MEDIVATION NEUROLOGY, INC. , BACHURIN, Sergey, Olegovich , GARIBOVA, Taisiya, Leonovna , VORONINA, Tatiana, Alexandrovna , GRIGORIEV, Vladimir, Viktorovich
发明人： BACHURIN, Sergey, Olegovich , GARIBOVA, Taisiya, Leonovna , VORONINA, Tatiana, Alexandrovna , GRIGORIEV, Vladimir, Viktorovich
IPC分类号： A01N43/38 , A01N43/42 , A61K31/405
CPC分类号： A61K31/437
摘要： A means for the treatment of insult based on hydrogenated pyrido (4, 3-b) indoles (variants) of formula (1) or formula (2) a pharmacological means based thereon and a method for the use thereof relate to the use of chemical compounds in the field of medicine and may be used for the treatment of ischemic and hemorrhagic insults and their consequences.
摘要翻译：用于基于式（1）或式（2）的氢化吡啶并（4,3-b）吲哚（变体）治疗侮辱的手段，其基于药理学手段，其使用方法涉及使用化学药物领域的化合物，可用于治疗缺血性和出血性损伤及其后果。

5. 发明申请

WO2011039675A3 LATREPIRDINE TRANSDERMAL THERAPEUTIC DOSAGE FORMS 审中-公开
公开(公告)号：WO2011039675A3
公开(公告)日：2011-04-07
申请号：PCT/IB2010/054241
申请日：2010-09-20
申请人： PFIZER INC. , MEDIVATION NEUROLOGY, INC. , BARTLETT, Jeremy Adam , MURPHY, Brendan John , RANADE, Gautam Ramachandra , YEOH, Thean Yeow , ZIEGLER, JR., Carl Bernard , WOLLOWITZ, Susan , MATZ, Sheila
发明人： BARTLETT, Jeremy Adam , MURPHY, Brendan John , RANADE, Gautam Ramachandra , YEOH, Thean Yeow , ZIEGLER, JR., Carl Bernard , WOLLOWITZ, Susan , MATZ, Sheila
IPC分类号： A61K9/70 , A61K9/06 , A61K9/00
摘要： The present invention provides transdermal formulations comprising latrepirdine or pharmaceutically acceptable salts thereof having desirable pharmacokinetic characteristics. Also provided are novel transdermal compositions and their manufacture.

6. 发明申请

WO2008036400A3 HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME 审中-公开
标题翻译：氢化吡喃葡萄糖[4,3-B]吲哚等，用于治疗犬精神功能障碍综合征
公开(公告)号：WO2008036400A3
公开(公告)日：2008-06-19
申请号：PCT/US2007020483
申请日：2007-09-20
申请人： MEDIVATION NEUROLOGY INC , HUNG DAVID
发明人： HUNG DAVID
IPC分类号： A61K31/437 , A61P25/28
CPC分类号： A61K31/437
摘要： The invention provides method for treating Cognitive Dysfunction Syndrome (CCDS), slowing the onset and/or development and/or progression of CCDS or preventing the development of CCDS in canines, such as dogs, using hydrogenated pyrido [4,3-b] indoles, including dimebon.
摘要翻译：本发明提供用于治疗认知功能障碍综合征（CCDS）的方法，使用氢化吡啶并[4,3-b]吲哚，减缓CCDS的发作和/或发展和/或进展，或阻止犬等犬类如CCD的发展，包括dimebon。

7. 发明申请

WO2008147551A8 METHODS AND COMPOSITIONS FOR STIMULATING CELLS 审中-公开
标题翻译：刺激细胞的方法和组合物
公开(公告)号：WO2008147551A8
公开(公告)日：2010-01-07
申请号：PCT/US2008006667
申请日：2008-05-23
申请人： MEDIVATION NEUROLOGY INC , HUNG DAVID T , PROTTER ANDREW ASHER
发明人： HUNG DAVID T , PROTTER ANDREW ASHER
IPC分类号： A61K31/44
CPC分类号： A61K31/44
摘要： The invention provides compositions and methods for treating, preventing, delaying the onset, and/or delaying the development of a disease or condition for which the activation, differentiation, and/or proliferation of one or more cell types is beneficial. These compositions and methods include, for example, a hydrogenated pyrido [4,3 -b] indole such as dimebon and/or a cell that has been incubated with a hydrogenated pyrido [4,3 -b] indole such as dimebon. In some embodiments, the compositions and methods also include a growth factor and/or an anti-cell death compound. The invention also provides methods of activating a cell, promoting the differentiation of a cell, and/or promoting the proliferation of a cell by incubating the cell with one or more hydrogenated pyrido [4,3 -b] indoles or pharmaceutically acceptable salts thereof. In some embodiments, the cell is also incubated with one or more growth factors and/or anti-cell death compounds.
摘要翻译：本发明提供用于治疗，预防，延缓发作和/或延缓一种或多种细胞类型的活化，分化和/或增殖有益的疾病或病症的发展的组合物和方法。这些组合物和方法包括例如氢化吡啶并[4,3-b]吲哚（如二甲氧基）和/或已经与氢化吡啶并[4,3-b]吲哚（如二甲氧基）温育的细胞。在一些实施方案中，组合物和方法还包括生长因子和/或抗细胞死亡化合物。本发明还提供了通过将细胞与一种或多种氢化吡啶并[4,3-b]吲哚或其药学上可接受的盐一起孵育来激活细胞，促进细胞分化和/或促进细胞增殖的方法。在一些实施方案中，细胞还与一种或多种生长因子和/或抗细胞死亡化合物一起温育。

8. 发明申请

WO2009039420A9 METHODS AND COMPOSITIONS FOR TREATING NEURONAL DEATH MEDIATED OCULAR DISEASES 审中-公开
公开(公告)号：WO2009039420A9
公开(公告)日：2009-03-26
申请号：PCT/US2008/077090
申请日：2008-09-19
申请人： MEDIVATION NEUROLOGY, INC. , HUNG, David, T.
发明人： HUNG, David, T.
IPC分类号： A01N43/38 , A61K31/405
摘要： The invention provides methods for treating and/or preventing and/or slowing the onset and/or development of a neuronal death mediated ocular disease using hydrogenated pyrido[4,3- b]indoles, such as dimebon.

9. 发明申请

WO2009017836A1 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA USING ANTIPSYCHOTIC COMBINATION THERAPY 审中-公开
标题翻译：使用抗生素治疗治疗精神病药的方法和组合物
公开(公告)号：WO2009017836A1
公开(公告)日：2009-02-05
申请号：PCT/US2008/009357
申请日：2008-08-01
申请人： MEDIVATION NEUROLOGY, INC. , BACHURIN, Sergey, Olegovich , GRIGORIEV, Vladimir, Viktorovich , MOROZOVA, Margarita, A. , BENIASHVILI, Allan, G.
发明人： BACHURIN, Sergey, Olegovich , GRIGORIEV, Vladimir, Viktorovich , MOROZOVA, Margarita, A. , BENIASHVILI, Allan, G.
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K45/06 , A61K31/44 , A61K31/519 , A61K31/5415 , A61K2300/00
摘要： The present invention relates to combination therapies and methods for treating, preventing and/or delaying the onset and/or development of schizophrenia, wherein the combination therapies comprise a hydrogenated pyrido[4,3 -b]indole or a pharmaceutically acceptable salt thereof, such as dimebon, and an antipsychotic.
摘要翻译：本发明涉及用于治疗，预防和/或延迟精神分裂症的发作和/或发展的组合疗法和方法，其中所述联合治疗包括氢化吡啶并[4,3-b]吲哚或其药学上可接受的盐，作为dimebon和抗精神病药。

10. 发明申请

WO2011039675A2 LATREPIRDINE TRANSDERMAL THERAPEUTIC DOSAGE FORMS 审中-公开
标题翻译： LATREPIRDINE TRANSDERMAL治疗剂型
公开(公告)号：WO2011039675A2
公开(公告)日：2011-04-07
申请号：PCT/IB2010054241
申请日：2010-09-20
申请人： PFIZER , MEDIVATION NEUROLOGY INC , BARTLETT JEREMY ADAM , MURPHY BRENDAN JOHN , RANADE GAUTAM RAMACHANDRA , YEOH THEAN YEOW , ZIEGLER JR CARL BERNARD , WOLLOWITZ SUSAN , MATZ SHEILA
发明人： BARTLETT JEREMY ADAM , MURPHY BRENDAN JOHN , RANADE GAUTAM RAMACHANDRA , YEOH THEAN YEOW , ZIEGLER JR CARL BERNARD , WOLLOWITZ SUSAN , MATZ SHEILA
CPC分类号： A61K9/7069 , A61K9/0014 , A61K9/06 , A61K9/7015 , A61K9/7053 , A61K9/7061 , A61K9/7076
摘要： The present invention provides transdermal formulations comprising latrepirdine or pharmaceutically acceptable salts thereof having desirable pharmacokinetic characteristics. Also provided are novel transdermal compositions and their manufacture.
摘要翻译：本发明提供了包含具有所需药代动力学特征的纬毒素或其药学上可接受的盐的透皮制剂。还提供了新型透皮组合物及其制造方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式